ArticleJournal of thoracic disease2025
Efficacy and safety of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: an updated systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Surgical and pathologic efficacy of neoadjuvant immunochemotherapy in EGFR-mutant non-small cell lung cancer.Translational lung cancer research · 2026Article
- Global trends and research progress on immunotherapy forJournal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment options for lung cancer patients with epidermal growth factor receptor (EGFR) mutations are limited after tyrosine kinase inhibitor (TKI) resistance. We aimed to evaluate the efficacy and safety of immune checkpoint inhibitors (ICIs) in patients with EGFR-TKI-resistant non-small cell lung cancer (NSCLC). Methods: We retrieved randomized controlled trials (RCTs) on ICIs in patients with EGFR-TKI resistance from PubMed, Cochrane Library, Web of Science, and EMBASE databases from creation to March 25, 2025. We focused on the endpoints median overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and safety data. Results: Twelve eligible RCTs were included in this meta-analysis. The combination of ICIs and chemotherapy was better than chemotherapy alone [PFS: hazard ratio (HR) =0.76, 95% confidence interval (CI): 0.66-0.87, P<0.001; OS: HR =0.86, 95% CI: 0.75-1.00, P=0.045]. ICIs plus anti-angiogenic agents and chemotherapy also improved PFS (HR =0.51, 95% CI: 0.43-0.61), P<0.001), but not OS (HR =0.91, 95% CI: 0.76-1.10, P=0.34). No significant differences were observed in all-grade treatment-related adverse events (TRAEs) between ICIs-based treatment and chemotherapy (RR =1.34, 95% CI: 0.71-2.54, P=0.27). Conclusions: In patients with EGFR-TKI-resistant NSCLC, the combination of ICIs with chemotherapy significantly improved both PFS and OS compared to chemotherapy alone, while ICIs, chemotherapy, and anti-angiogenic drugs only enhanced PFS. The ICIs-chemotherapy regimen demonstrates acceptable safety, suggesting its potential as a therapeutic option that deserve further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.